| Project/Area Number |
18K07398
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 51030:Pathophysiologic neuroscience-related
|
|---|
| Research Institution | Toho University |
|---|
Principal Investigator |
Kano Osamu 東邦大学, 医学部, 教授 (20459762)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
星 秀夫 東邦大学, 医学部, 講師 (30568382)
|
|---|
| Project Period (FY) |
2018-04-01 – 2022-03-31
|
| Project Status |
Completed (Fiscal Year 2021)
|
| Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2021: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2020: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2019: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2018: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
|
|---|
| Keywords | 筋萎縮性側索硬化症 / バイオマーカー / 神経変性疾患 / 酸化ストレス |
|---|
| Outline of Final Research Achievements |
We have focused on neuronal apoptosis inhibitory protein (NAIP) in peripheral blood, which selectively inhibits oxidative stress-induced cell death and may be a potential biomarker for diagnosis and progression of amyotrophic lateral sclerosis (ALS), as well as a molecular indicator of therapeutic drug efficacy. We have shown that NAIP is a potential biomarker for the diagnosis and progression of ALS and for the efficacy of therapeutic drugs. As a next step, we have demonstrated a more convenient method for protein analysis of NAIP in peripheral blood and quantification of NAIP-RNA in patients with neurodegenerative diseases (ALS, Parkinson's disease, and Alzheimer's disease) and healthy subjects.
|
| Academic Significance and Societal Importance of the Research Achievements |
NAIPがALSをはじめとした神経変性疾患の診断のバイオマーカーとして確立されれば、早期診断、早期治療介入が可能になり、患者の生命予後延長のみならず、介護者を含めたQOLの向上に繋がると推測される。将来的には治療ターゲットとしてNAIPの産生を誘導する化合物が重要になり、創薬分野への新たな方向性を示すことが可能になる。
|
